Hemostemix (HEM) Trading Down 12.5%

Hemostemix Inc (CVE:HEM) shares were down 12.5% during mid-day trading on Tuesday . The company traded as low as C$0.11 and last traded at C$0.11. Approximately 200,000 shares were traded during mid-day trading, a decline of 25% from the average daily volume of 266,036 shares. The stock had previously closed at C$0.12.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by Community Financial News and is the property of of Community Financial News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.com-unik.info/2018/12/04/hemostemix-hem-trading-down-12-5.html.

About Hemostemix (CVE:HEM)

Hemostemix Inc, a clinical-stage biotechnology company, develops, manufactures, and commercializes blood-derived cell therapies for medical conditions in Canada. It develops cell therapy products from the patient's own blood, a relatively non-invasive source of therapeutic cells. The company's lead product is ACP-01, which is in Phase II clinical trial for the treatment of critical limb ischemia.

Further Reading: What is the Federal Reserve?

Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit